Ni Hms 672407
Ni Hms 672407
Ni Hms 672407
Author manuscript
Hypertension. Author manuscript; available in PMC 2016 June 01.
Author Manuscript
Abstract
Author Manuscript
member 14). SiRNA knockdown experiments also demonstrated that elevated HIF-1α contributed
to LIGHT-induced PE features. Translational studies with human placentas showed that AT1-AA
or LIGHT is capable of inducing HIF-1α in a hypoxia-independent manner. Moreover, increased
HIF-1α was found to be responsible for AT1-AA or LIGHT-induced elevation of Flt-1 gene
expression and production of sFlt-1 in human villous explants. Overall, we demonstrated that
hypoxia-independent stimulation of HIF-1α gene expression in the placenta is a common
*
Correspondence: Yang Xia, Department of Biochemistry & Molecular Biology, University of Texas Medical School at Houston. Tel:
713-500-5039/ Fax: 713-500-0652/ yang.xia@uth.tmc.edu.
Disclosures
none.
Iriyama et al. Page 2
pathogenic mechanism promoting disease progression. Our findings reveal new insight to PE and
Author Manuscript
Keywords
preeclampsia; hypoxia inducible factor-1α; angiotensin II type I receptor agonistic autoantibody;
tumor necrosis factor superfamily member 14; soluble fms-like tyrosine kinase-1
Introduction
Preeclampsia (PE) is a life threating hypertensive complication of pregnancy and is a leading
causes of maternal and neonatal morbidity and mortality1, 2. Despite intensive research
efforts and several large clinical trials, current strategies for managing PE remain inadequate
and are limited to symptomatic therapy or the termination of pregnancy. Thus, uncovering
Author Manuscript
novel factors and signaling pathways that contribute to the pathogenesis of PE are needed
for the establishment of mechanism-based preventative and therapeutic strategies to improve
the prognosis of the disease.
Hypoxia-inducible factor-1 (HIF-1) is a key transcription factor that plays a central role in
the cellular response to low oxygen tension under physiologic and pathologic conditions3, 4.
HIF-1α is a heterodimer consisting of two subunits, α and β. Although HIF-1β is
constitutively expressed, HIF-1α levels are precisely regulated by post-translational
modification depending on oxygen tension. HIF-1α is rapidly degraded under normoxic
conditions, but quickly stabilized when oxygen availability is reduced. Thus, hypoxia-
induced HIF-1α is usually transient and brief at the protein level4. A variety of studies have
shown that women with PE are characterized by persistently elevated placental HIF-1α
Author Manuscript
levels that promote enhanced transcription of genes encoding soluble fms-like tyrosine
kinase-1 (sFlt-1), soluble endoglin (sEng) and endothelin-1 (ET-1), all known to contribute
to PE5–7. However, the molecular basis underlying prolonged elevated placental HIF-1α in
PE and the pathological role of sustained elevated HIF-1α in PE are largely unknown.
Numerous recent studies have shown that HIF-1α levels can be regulated by means that are
independent of hypoxia8. For example, angiotensin II and the inflammatory cytokines TNF
and IL-6 induce HIF-1α gene expression in vascular smooth muscle cells, kidney cells and
hepatocytes, respectively9–11. Multiple studies have revealed that inflammatory cytokines
and autoantibodies are elevated in PE patients and contribute to pathophysiology PE12–14.
For example, early studies showed that injection or infusion of pathogenic autoantibodies
such as the angiotensin II type 1 receptor agonistic autoantibody (AT1-AA) or the
Author Manuscript
Methods
Author Manuscript
For detailed descriptions, refer to the Methods section in the online-only Data Supplement.
Results
Increased placental HIF-1α contributes to the development of PE features in an
autoantibody-injection model of PE in pregnant mice
In order to examine a potential role of elevated HIF-1α in PE, we took advantage of an
experimental model of PE in mice induced by the injection of patient-derived-IgG (PE-IgG)
known to contain the pathogenic autoantibodies, AT1-AA17. We found that Hif-1α gene
expression was induced significantly in the placentas of mice injected with PE-IgG
compared to the pregnant mice injected with IgG from normotensive pregnant women (NT-
IgG) (Figure 1A). In contrast, no significant difference was observed in the kidneys between
Author Manuscript
PE-IgG and NT-IgG-injected pregnant mice (Figure S1). We also confirmed that PE-IgG
induced the elevation of placental HIF-1α expression at the protein level by immunoblotting
(Figure 1B). Additionally, immunohistochemical analysis revealed that the PE-IgG induced
elevation of HIF-1α protein expression throughout the placenta (Figure 1C and Figure 1D).
In addition, the PE-IgG-induced elevation of placental HIF-1α expression was almost
completely inhibited when PE-IgG was coinjected with losartan, an angiotensin II type 1
receptor (AT1R) blocker, or with the autoantibody-neutralizing 7 amino acid epitope peptide
(Figure 1A, 1B, 1C, and 1D). These results indicate that the elevation of placental HIF-1α
resulting from injection PE-IgG was due to the activation of AT1Rs by AT1-AA.
glomeruli with narrowed capillary and Bowman’s spaces) were attenuated in the kidneys of
Hif-1α siRNA-injected mice (Figure 2D). Additionally, we found that placentas of Hif-1α
siRNA-injected mice displayed significantly less tissue damage including placental
calcifications, a hallmark of placental distress observed in placentas of PE patients, as
compared with those of control siRNA-injected mice (Figure S3). Moreover, we examined
placental vasculature using CD31 staining. As a result, PE-IgG-induced disorganized and
impaired vasculature in the labyrinthine zone of control siRNA-injected mice (low density of
CD31-positive vessels and narrowed capillary spaces) was attenuated in the placentas of
Author Manuscript
The Flt-1 gene is a direct transcriptional target of HIF-1α19. A splice variant encodes soluble
Flt-1 (sFlt-1), an antiangiogenic factor secreted by the placenta into the maternal circulation,
that is believed to contribute to the development of systemic endothelial dysfunction,
hypertension and multi-organ damage, including the kidneys in PE patients20. As such, we
also found that Hif-1α mRNA knockdown in vivo suppressed the PE-IgG-induced elevation
of Flt-1 mRNA in the placenta, as well as circulating sFlt-1 levels (Figure 2F and Figure
2G). These results provide in vivo evidence that the induction of HIF-1α in the placenta
contributes to the development of pathogenic autoantibody-induced features of PE and is
also involved in the increased sFlt-1 production.
To assess whether elevated HIF-1α in the placenta plays a detrimental role in the LIGHT-
induced PE development as it does in PE-IgG-injected mice, we conducted in vivo knock-
down of Hif-1α mRNA by injecting Hif-1α siRNA-encapsulated nanoparticles, together
with LIGHT, into pregnant mice. Hif-1α siRNA injection successfully reduced the levels of
placental Hif-1α mRNA compared with those of control siRNA-injected mice (Figure 3A).
Moreover, preeclamptic features induced by LIGHT injection (hypertension and proteinuria)
were attenuated significantly in Hif-1α siRNA-injected pregnant mice compared with
control siRNA-injected pregnant mice (Figure 3B and Figure 3C). Additionally we found
that Hif-1α mRNA knockdown attenuated the PE-IgG-induced elevation of Flt-1 mRNA
levels, as well as circulating sFlt-1 protein (Figure 3D and Figure 3E). These findings
indicate that placental elevated HIF-1α contributes to the development of PE features in the
Author Manuscript
LIGHT can directly induce HIF-1α gene expression in the human placenta independent of
Author Manuscript
hypoxia, we used primary human placental villous explants isolated from normotensive
pregnant women. We cultured human villous explants treated with PE-IgG, NT-IgG or
LIGHT under ambient oxygen levels. We found that PE-IgG significantly induced HIF-1α
mRNA levels compared to the NT-IgG-treated human villous explants and the induction was
significantly reduced by co-treatment with losartan to inhibit AT1R activation or 7 amino
acid epitope peptide to neutralize AT1-AA (Figure 4D). Similarly, we found that treatment of
cultured villous explants with LIGHT resulted in increased HIF-1α mRNA levels compared
to the controls (Figure 4E). Additionally, we also confirmed that PE-IgG or LIGHT induced
the elevation of HIF-1α protein (Figure 4F). Thus, these results indicate that AT1-AA and
LIGHT are capable of directly inducing HIF-1α gene expression in cultured human villous
explants independent of hypoxia.
AT1-AA or LIGHT-induced HIF-1α promotes FLT-1 gene expression and subsequent sFlt-1
Author Manuscript
HIF-1α for Flt-1 gene induction and subsequent sFlt-1 production induced by PE-IgG or
LIGHT, we conducted HIF-1α mRNA knockdown in human villous explants. We confirmed
that the elevation of HIF-1α induced by PE-IgG or LIGHT was successfully down-regulated
by the treatment of HIF-1α siRNA compared with control scrambled siRNA-treated group
(Figure 5D). The increase in Flt-1 mRNA levels and the amount of secreted sFlt-1 induced
by PE-IgG or LIGHT were significantly suppressed by the knockdown of HIF-1α mRNA in
human villous explants (Figure 5E and Figure 5F). These results indicate that PE-IgG or
LIGHT directly induces FLT-1 gene expression in a HIF-1α-dependent manner in cultured
human villous explants independent of hypoxia.
Discussion
Here we report that Hif-1α mRNA and HIF-1α protein levels were elevated in the placentas
Author Manuscript
of two independent animal models of PE, based on the injection with AT1-AA or LIGHT.
We also showed that specific siRNA knockdown of Hif-1α mRNA attenuated hallmark
features of PE including hypertension, proteinuria, kidney damage, impaired placental
vasculature, and maternal elevated circulating sFlt-1 in both PE mouse models. These results
indicate that increased HIF-1α gene expression is a common pathogenic factor contributing
to PE. Extending animal studies to humans, we confirmed that HIF-1α mRNA and HIF-1α
protein levels were elevated in the placentas of PE patients. Using human villous explant
mRNA and HIF-1α protein levels resulting in elevated FLT-1 mRNA levels and increased
sFlt-1 secretion in a hypoxia-independent manner. Overall, we provide both in vivo animal
studies and in vitro human evidence showing the pathogenic role of elevated HIF-1α gene
expression in PE and hypoxia-independent mechanisms underlying its elevation in the
placentas.
Numerous early studies showed that HIF-1α can be induced by non-hypoxic stimuli in
various cell types6. For example, studies in vascular smooth muscle cells showed that
angiotensin II (Ang II) stimulates HIF-1α production by a protein kinase C-mediated
transcriptional activation of the HIF-1α gene expression and by a reactive oxygen species-
dependent mechanism leading to enhanced translation of HIF-1α mRNA10, 21. In this case,
Ang II induces HIF-1α protein leading to an increase in vascular endothelial growth factor
gene expression. Other studies have shown that Ang II induces HIF-1α mRNA production in
Author Manuscript
renal glomerular cells22. Women with PE harbor autoantibodies (AT1-AA) that mimic the
action of Ang II, and activate the major angiotensin receptor, AT1R. These pathogenic
autoantibodies may serve as hypoxia-independent factors leading to the increased production
of HIF-1α observed in placentas of women with PE. Supporting our hypothesis, we have
provided human in vitro studies showing that purified PE-IgG, which contains AT1-AA,
activates AT1Rs resulting in the induction of HIF-1α gene expression under non-hypoxic
conditions. Additionally, we demonstrated that HIF-1α expression is induced significantly in
the placentas of mice injected with PE-IgG. We realize that the PE-IgG used in our
experiment is a complex mixture of immunoglobulins that is likely to contain other
autoantibodies. However, we have shown in prior publications that the same effects are seen
when AT1-AA is specifically purified by affinity chromatography17. Furthermore, the PE-
IgG or affinity purified AT1-AA-induced PE features are blocked by losartan or the 7aa
Author Manuscript
epitope peptide, indicating that the effects are mediated by interaction with the specific
epitope on the AT1 receptor. Our results are also in good agreement with those Wenzel et al.
who showed that pregnant rats infused with a rabbit antibody that activates AT1Rs resulted
in elevated HIF-1α in rat placentas23. Our current study has provided human and mouse
evidence that the activation of AT1Rs by AT1-AA induces HIF-1α gene expression in the
placenta, and thereby contributing to the development of PE.
cytokines is an early event in the development of PE, and functions upstream of AT1-AA
production. Additional evidence shows that inflammatory cytokines induce HIF-1α under
non-hypoxic conditions6. For example, TNF-α and IL-1β activate HIF-1α gene expression in
human hepatoma cells24. TNF-α increases HIF-1α mRNA levels as well as its target genes
GLUT-1 and GLUT-3 in HEK293 cells9. IL-6 induces both HIF-1α mRNA and HIF-1α
protein levels, and the expression of the HIF-1α target gene, erythropoietin, in
hepatocytes11. IL-1β induces HIF-1α-mediated VEGF secretion in trophoblast cells25. Thus,
a pathogenic role for HIF-1α in response to elevated inflammatory cytokines associated with
in vivo animal and in vitro human evidence that AT1-AA and LIGHT are two hypoxia-
independent factors that stimulate Hif-1α gene expression resulting in subsequent HIF-1α-
mediated activation of Flt-1 gene expression. Our studies support a working model (Figure
5G) in which AT1-AA or LIGHT-induced HIF-1α expression in placental trophoblasts is
followed by HIF-1α-mediated induction of Flt-1 gene expression and subsequent sFlt-1
production independent of hypoxia. Considerable evidence now indicates that elevated
production of sFlt-1 plays a pathogenic role in PE20. Thus, interfering with persistently
elevated HIF-1α is likely to reduce the overproduction of sFlt-1 and slow the progression of
the disease (Figure 5G).
Perspectives
In conclusion, our current studies have added significant new insight to the pathogenesis of
Author Manuscript
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Author Manuscript
Acknowledgments
Sources of funding
This work was supported by National Institute of Health Grants HL119549 (to YX), RC4HD067977 and HD34130
(to YX and REK), and by China National Science Foundation 81228004 (to YX).
References
Author Manuscript
1. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet. 2001; 357:53–56.
[PubMed: 11197372]
2. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010; 376:631–
644. [PubMed: 20598363]
3. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012; 148:399–408.
[PubMed: 22304911]
4. Greer SN, Mestcalf JL, Wang Y, Ohh M. The updated biology of hypoxia-inducible factor. The
EMBO journal. 2012; 31:2448–2460. [PubMed: 22562152]
5. Rajakumar A, Brandon HM, Daftary A, Ness R, Conrad KP. Evidence for the functional activity of
hypoxia-inducible transcription factors overexpressed in preeclamptic placentae. Placenta. 2004;
25:763–769. [PubMed: 15451190]
6. Pringle KG, Kind KL, Sferruzzi-Perri AN, Thompson JG, Roberts CT. Beyond oxygen: Complex
regulation and activity of hypoxia inducible factors in pregnancy. Human reproduction update.
2010; 16:415–431. [PubMed: 19926662]
Author Manuscript
factor-alpha, and agonistic autoantibodies to the angiotensin ii type i receptor on soluble fms-like
tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy.
American journal of hypertension. 2010; 23:911–916. [PubMed: 20431529]
17. Zhou CC, Zhang Y, Irani RA, Zhang H, Mi T, Popek EJ, Hicks MJ, Ramin SM, Kellems RE, Xia
Y. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nature
medicine. 2008; 14:855–862.
18. Kotch LE, Iyer NV, Laughner E, Semenza GL. Defective vascularization of hif-1alpha-null
embryos is not associated with vegf deficiency but with mesenchymal cell death. Developmental
biology. 1999; 209:254–267. [PubMed: 10328919]
19. Gerber HP, Condorelli F, Park J, Ferrara N. Differential transcriptional regulation of the two
vascular endothelial growth factor receptor genes. Flt-1, but not flk-1/kdr, is up-regulated by
Author Manuscript
What is new?
• HIF-1α gene expression and protein levels were induced in the placentas of two
independent animal models of PE infused with AT1-AA or LIGHT.
• Using human villous explant culture, we found that AT1-AA or LIGHT directly
induced HIF-1α gene expression and upregulated HIF-1α was responsible for
AT1-AA or LIGHT-induced elevation of Flt-1 gene expression and the
Author Manuscript
What is relevant?
Our current studies have provided new insight to the pathogenesis of PE by identifying
the detrimental role of chronically elevated placental HIF-1α initially triggered by
hypoxia-independent factors. Additionally, our discoveries indicate therapeutic
possibilities targeting HIF-1α.
Summary
We have provided both mouse and human evidence that increased HIF-1α in the placenta
plays a general pathologic role in the pathogenesis of PE induced by a pathogenic
autoantibody or an inflammatory cytokine. Our findings highlight novel therapeutic
possibilities for PE.
Author Manuscript
Author Manuscript
Pregnant mice were injected with purified IgG from normotensive pregnant women (NT-
IgG) or PE patients (PE-IgG) on E13.5 and E14.5. Losartan (Los), an angiotensin II receptor
antagonist, or autoantibody-neutralizing 7 amino acid epitope peptide (7aa) were in some
cases co-injected with PE-IgG. Samples were collected on E18.5.
(A) Placental Hif-α mRNA expression was quantified by real-time RT-PCR. (NT-IgG; n=6
mice, PE-IgG; n=7, PE-IgG+Los; n=4, PE-IgG+7aa; n=4), (**P<0.01 vs NT-IgG, ##P<0.01
vs PE-IgG)
(B) Increase in placental HIF-1α protein level in mice injected with PE-IgG was detected by
Author Manuscript
immunoblotting.
(C) HIF-1α protein in mouse placentas detected by immunohistochemistry (IHC). Arrows
indicate the cells with positive staining in the nucleus. Scale bar, upper; 500µm, lower;
50µm. (Sp; spongiotrophoblast zone Lb; labyrinth zone)
(D) The positive staining for HIF-1α was quantified. (n=6 fields per placenta under ×100
magnification; 4 mice per group), (**P<0.01 vs NT-IgG, #P<0.05, ##P<0.01 vs PE-IgG)
Author Manuscript
Author Manuscript
Author Manuscript
Fig. 2. In vivo specific knockdown of Hif-1α mRNA prevents the development of PE features
Author Manuscript
induced by AT1-AA
In vivo siRNA-mediated Hif-1α mRNA knockdown was performed.
(A) The levels of Hif-1α mRNA in mouse placentas were quantified by real-time RT-PCR.
(n=6 mice per group), (**P<0.01 vs NT-IgG, ##P<0.01 vs PE-IgG+control siRNA)
(B) Blood pressure was measured by tail-cuff plethysmography on a daily base. (n=6 mice
per group), (*P<0.05, **P<0.01 vs NT-IgG, ##P<0.01 vs PE-IgG+control siRNA at the same
time points)
(C) Proteinuria was determined as urine albumin to creatinine ratio by ELISA. (n=6 mice
per group), (*P<0.05 vs NT-IgG, ##P<0.01 vs PE-IgG+control siRNA)
Author Manuscript
(D) Renal histology assessed by PAS staining. Pathologic changes in kidneys of PE-IgG-
treated WT mice (swollen glomeruli with narrowed capillary and Bowman’s spaces) were
suppressed by siRNA knockdown of Hif-1α mRNA. Scale bar, 100µm.
(E) The staining of CD31, an endothelial cell marker, by immunohistochemistry (IHC) /
immunofluorescence (IF). Scale bar, 200µm.
(F) The levels of Flt-1 mRNA in mouse placentas were quantified by real-time RT-PCR.
(n=6 mice per group), (**P<0.01 vs NT-IgG, #P<0.05 vs PE-IgG+control siRNA)
(G) The levels of circulating sFlt-1 in mouse plasma were determined by ELISA. (n=6 mice
per group), (*P<0.05 vs NT-IgG, #P<0.05 vs PE-IgG+control siRNA)
Author Manuscript
Author Manuscript
Author Manuscript
Fig. 3. Specific knockdown of mRNA in vivo suppresses the features of PE induced by LIGHT
Pregnant mice were injected with saline or LIGHT with or without neutralizing antibodies
against lymphotoxin β receptor (anti-LTβR) or herpes virus entry mediator (anti-HVEM) on
E13.5 and E14.5. Additionally, in vivo siRNA-mediated Hif-1α mRNA knock down was
conducted. Samples were collected on E18.5.
Author Manuscript
(A) Placental Hif-1α mRNA levels were quantified using real-time RT-PCR. (n=4–7 mice
per group), (**P<0.01 vs saline, #P<0.05 vs LIGHT, ††P<0.01 vs LIGHT+control siRNA)
(B) Blood pressure was measured by tail-cuff plethysmography on a daily base. (n=5–6 mice
per group), (*P<0.05, **P<0.01 vs saline, ##P<0.01 vs LIGHT+control siRNA at the same
time points)
(C) Proteinuria was determined as urine albumin to creatinine ratio by ELISA. (n=5–6 mice
per group), (*P<0.05 vs saline, ##P<0.01 vs LIGHT+control siRNA)
(D) Placental Flt-1 mRNA levels were quantified using real-time RT-PCR. (n=5–6 mice per
group), (**P<0.01 vs saline, #P<0.05 vs LIGHT + control siRNA)
Author Manuscript
(E) The levels of circulating sFlt-1 in mouse plasma were determined by ELISA. (n=6–7
mice per group), (**P<0.01 vs saline, #P<0.05 vs LIGHT+control siRNA)
Author Manuscript
Author Manuscript
Author Manuscript
Fig. 4. AT1-AA or LIGHT is capable of directly inducing HIF-1α gene expression in human
villous explants independent of hypoxia
(A) Placental HIF-1α mRNA levels, determined by real-time RT-PCR, were increased in
preeclampsia patients (PE) compared with normotensive pregnant women (NT). (n=10 per
group), (*P<0.05 vs NT)
(B) The elevated levels of HIF-1α protein in placentas of PE patients is detected by
immunohistochemistry. Scale bar, 200µm.
(C) The positive staining for HIF-1α was quantified. (n=6 fields per section under ×100
magnification; NT; n=4, PE; n=5), (*P<0.05 vs NT)
(D) Human villous explants were treated with 100µg/ml NT-IgG or PE-IgG for 24 hours in
the presence or absence of 5uM Losartan (Los) or 1uM autoantibody-neutralizing 7 amino
acid epitope peptide (7aa). HIF-1α mRNA levels were quantified using real-time RT-PCR.
(n=3 independent experiments), (**P<0.01 vs NT-IgG, ##P<0.01 vs PE-IgG)
Author Manuscript
(E) HIF-1α mRNA levels in cultured human villous explants treated with 100pg/ml LIGHT
for 24 hours were quantified using real-time RT-PCR. (n=3 independent experiments),
(**P<0.01 vs saline injected mice)
(F) HIF-1α protein levels following treatment with IgG or LIGHT as described in D or E
was assessed by immunoblotting. (NS: non-specific bands)
Fig. 5. HIF-1α is responsible for AT1-AA or LIGHT-induced elevation of Flt-1 gene expressioin
Author Manuscript
(B) FLT-1 mRNA levels were quantified using real-time RT-PCR. (n=4 independent
experiments), (**P<0.01 vs NT-IgG or PBS-treated group, #P<0.05, ##P<0.01 vs PE-IgG or
Author Manuscript
LIGHT-treated group)
(C) Secreted sFLT-1 protein levels in the culture media were determined by ELISA. (n=5
independent experiments), (**P<0.01 vs NT-IgG or PBS-treated group, #P<0.05 vs PE-IgG
or LIGHT-treated group)
(D) Knockdown of HIF-1α in human villous explants. The explants were treated with
nanoparticle encapsulated control (con) -or HIF-1α-siRNA for 24 hours and then were
treated with NT- or PE-IgG (100µg /ml) or LIGHT (100 pg/mL) for 24 hours. HIF-1α
protein was assessed by immunoblotting.
(E) FLT-1 mRNA levels of human villous explants were quantified using real-time RT-PCR.
(n=4 independent experiments), (**P<0.01 vs NT-IgG or PBS+control
siRNA, #P<0.05, ##P<0.01 vs PE-IgG or LIGHT+ control siRNA group)
Author Manuscript
(F) Secreted sFLT-1 protein levels in the culture media were determined by ELISA. (n=4
independent experiments), (**P<0.01 vs NT-IgG or PBS+control siRNA, ##P<0.01 vs PE-
IgG or LIGHT+ control siRNA group)
(G) Working model of our study. AT1-AA or LIGHT-induced HIF-1α production in
placental trophoblasts is followed by HIF-1α-mediated induction of FLT-1 gene expression
and subsequent sFLT-1 protein production independent of hypoxia. Persistent elevation of
HIF-1α causes chronic overproduction of sFLT-1 and contributes to impaired placental
vascular development, maternal endothelial dysfunction and disease progression.
Author Manuscript
Author Manuscript